GSK vs GILD

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 03, 2026

GSK

32.0
AI Score
VS
GILD Wins

GILD

46.4
AI Score

Investment Advisor Scores

GSK

32score
Recommendation
AVOID NEW MONEY

GILD

46score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric GSK GILD Winner
Forward P/E 9.7656 15.5521 GSK
PEG Ratio 6.1023 2.2696 GILD
Revenue Growth 5.3% 10.2% GILD
Earnings Growth -69.5% 54.8% GILD
Tradestie Score 32.0/100 46.4/100 GILD
Profit Margin 14.5% -10.6% GSK
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY HOLD GILD

Relative Price Performance (Last 90 Days)

GSK 1M: -6.8% · 3M: -11.4% GILD 1M: -3.3% · 3M: +11.7%

Current Technical Phase

GSK

Markdown
Sell / avoid

Price below a falling SMA50 (slope -2.1%), weak momentum, RSI 34

RSI (14): 33.8 · Price: $47.03

GILD

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 44

RSI (14): 44.0 · Price: $144.74

Fundamentals Snapshot

Metric GSK GILD
Market Cap — —
Forward P/E 9.4 14.6
Trailing P/E 15.5 —
Revenue (TTM) — —
Revenue Growth 0.1% 0.1%
Gross Margin 0.7% 0.8%
Operating Margin 0.3% 0.3%
EPS 3.05 -2.63
Dividend Yield 0.04% 0.02%

Frequently Asked Questions

Based on our detailed analysis, GILD is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.